ARCH Venture Management LLC Buys Shares of 1,820,634 Lyell Immunopharma, Inc. $LYEL

ARCH Venture Management LLC purchased a new position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) in the second quarter, HoldingsChannel reports. The firm purchased 1,820,634 shares of the company’s stock, valued at approximately $16,113,000. Lyell Immunopharma comprises 5.4% of ARCH Venture Management LLC’s investment portfolio, making the stock its 6th biggest position. ARCH Venture Management LLC owned approximately 0.09% of Lyell Immunopharma at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in LYEL. Almitas Capital LLC lifted its position in Lyell Immunopharma by 136.3% in the first quarter. Almitas Capital LLC now owns 2,482,606 shares of the company’s stock worth $1,336,000 after purchasing an additional 1,432,086 shares during the period. Acadian Asset Management LLC raised its stake in shares of Lyell Immunopharma by 204.2% in the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock worth $354,000 after buying an additional 443,614 shares in the last quarter. Nuveen LLC bought a new stake in shares of Lyell Immunopharma in the 1st quarter worth $345,000. AQR Capital Management LLC lifted its holdings in shares of Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock valued at $94,000 after buying an additional 154,327 shares during the period. Finally, RBF Capital LLC bought a new position in Lyell Immunopharma during the second quarter valued at about $884,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Trading Up 3.1%

Shares of Lyell Immunopharma stock opened at $34.46 on Friday. Lyell Immunopharma, Inc. has a 1 year low of $7.65 and a 1 year high of $35.16. The company has a market cap of $731.93 million, a P/E ratio of -1.50 and a beta of -0.11. The stock has a 50-day moving average price of $19.94 and a 200 day moving average price of $14.12.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.81) by $0.68. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.01 million. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%. On average, equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LYEL has been the topic of several research reports. HC Wainwright upgraded shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $20.00 to $45.00 in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Monday, September 1st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $45.00.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.